Profusa, Inc. (PFSA) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of a Special Meeting of Stockholders held by Profusa, Inc. on June 23, 2026. The meeting was conducted virtually to address corporate governance, capital structure adjustments, and strategic acquisitions.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on voting outcomes and corporate actions.
Material Changes and Voting Results
Stockholders representing 1,816,505 shares (out of 4,660,268 outstanding) voted on six proposals. Key outcomes include:
- Director Election: Lauren Chung was elected as a Class I director with 631,502 votes FOR, 0 AGAINST, and 132,479 WITHHELD.
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation allowing the Board to execute one or more reverse stock splits between a 1-for-5 and 1-for-200 ratio through June 23, 2028. The vote was 1,338,997 FOR and 459,350 AGAINST.
- Asset Acquisition (Bio Insights LLC): Approval was granted for the issuance of new convertible preferred stock and common stock to Bio Insights LLC as consideration for the PanOmics Assay assets. The vote was 592,053 FOR and 166,040 AGAINST.
- Promissory Note Conversion (NorthView Sponsor I LLC): Stockholders approved the potential issuance of shares exceeding 19.99% of outstanding common stock upon conversion of a promissory note. The vote was 560,833 FOR and 196,371 AGAINST.
- Equity Plan Increase: The 2025 Equity and Incentive Plan share pool was increased from 100,386 to 795,930 shares (an increase of 695,544 shares) to represent 15% of outstanding shares post-split. The vote was 530,693 FOR and 228,370 AGAINST.
- Adjournment Authority: The Board was authorized to adjourn the meeting to solicit additional proxies if necessary. The vote was 1,315,372 FOR and 486,390 AGAINST.
Guidance, Outlook, and Risks
The filing contains no forward-looking financial guidance or management commentary regarding future performance. The primary risks and contingencies identified are the potential dilution of existing shareholders due to the approved reverse stock split, the issuance of preferred stock for the Bio Insights acquisition, and the conversion of the NorthView Sponsor I LLC promissory note.
Investor Verification Checklist
- Verify the exact reverse stock split ratio and implementation date once determined by the Board.
- Review the definitive Asset Purchase Agreement with Bio Insights LLC to understand the valuation and terms of the PanOmics Assay acquisition.
- Examine the Note Modification and Conversion Agreement with NorthView Sponsor I LLC to assess the total potential share issuance upon conversion.
- Confirm the updated share count and dilution impact following the approved equity plan increase and potential reverse split.